Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T11:11:33.052Z.
Calculation as of: 2026-10-06T11:11:33.052Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3e31615b66e5acc6c2b7b3f8a521ec69124b31f47383f0f9627e8176a83f275d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
Definium Therapeutics, Inc.
Market Cap
$4.81B
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.78B
Free Cash Flow Yield
N/A
TTM Avg
5.69%
3Y Avg
5.69%
5Y Avg
5.69%
Market Cap
$4.92B
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.02B
Free Cash Flow Yield
0.66%
TTM Avg
0.53%
3Y Avg
0.53%
5Y Avg
0.53%
Market Cap
$5.20B
Free Cash Flow Yield
N/A
TTM Avg
3.62%
3Y Avg
3.62%
5Y Avg
3.62%
Market Cap
$5.20B
Free Cash Flow Yield
3.91%
TTM Avg
3.85%
3Y Avg
2.74%
5Y Avg
2.55%
Market Cap
$5.27B
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.35B
Free Cash Flow Yield
5.60%
TTM Avg
5.52%
3Y Avg
3.51%
5Y Avg
2.87%
Market Cap
$4.21B
Free Cash Flow Yield
N/A
TTM Avg
6.32%
3Y Avg
4.83%
5Y Avg
4.83%
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Definium Therapeutics, Inc. (DFTX) | $4.81B | N/A | N/A | N/A | N/A |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.78B | N/A | 5.69% | 5.69% | 5.69% |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.92B | N/A | N/A | N/A | N/A |
| BillionToOne, Inc. (BLLN)vs › | $5.02B | 0.66% | 0.53% | 0.53% | 0.53% |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.20B | N/A | 3.62% | 3.62% | 3.62% |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.20B | 3.91% | 3.85% | 2.74% | 2.55% |
| Cogent Biosciences, Inc. (COGT)vs › | $5.27B | N/A | N/A | N/A | N/A |
| Doximity, Inc. (DOCS)vs › | $5.35B | 5.60% | 5.52% | 3.51% | 2.87% |
| AbCellera Biologics Inc. (ABCL)vs › | $4.21B | N/A | 6.32% | 4.83% | 4.83% |
| CRISPR Therapeutics AG (CRSP)vs › | $5.53B | N/A | 8.07% | 4.52% | 4.52% |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
